title: Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine.
abstract: Prevaccination and 6-week postvaccination samples from the immunogenicity substudy (n = 2269) of the zoster vaccine (ZV) efficacy trial (N = 22 439) in 50-59-year-old subjects were examined for varicella-zoster virus-specific antibody responses to vaccination. The varicella-zoster virus geometric mean titer (GMT) and geometric mean fold rise were higher in ZV recipients than in placebo recipients (GMT, 660.0 vs 293.1 glycoprotein enzyme-linked immunosorbent assay units/mL [P < .001], respectively; geometric mean fold rise, 2.31 vs 1.00 [P < .025]). In each group there was a strong inverse correlation between postvaccination GMT and risk of subsequent herpes zoster. Although these data provide strong evidence that relates ZV-induced antibody and the risk of herpes zoster, a protective threshold was not determined. Clinical Trials Registration. NCT00534248.
authors.affiliation: University of Colorado Denver Anschutz Medical Campus, Aurora.
authors.forename: Myron J
authors.initials: MJ
authors.lastname: Levin
authors.forename: Kenneth E
authors.initials: KE
authors.lastname: Schmader
authors.forename: John W
authors.initials: JW
authors.lastname: Gnann
authors.forename: Shelly A
authors.initials: SA
authors.lastname: McNeil
authors.forename: Timo
authors.initials: T
authors.lastname: Vesikari
authors.forename: Robert F
authors.initials: RF
authors.lastname: Betts
authors.forename: Susan
authors.initials: S
authors.lastname: Keay
authors.forename: Jon E
authors.initials: JE
authors.lastname: Stek
authors.forename: Nickoya D
authors.initials: ND
authors.lastname: Bundick
authors.forename: Shu-Chih
authors.initials: SC
authors.lastname: Su
authors.forename: Yanli
authors.initials: Y
authors.lastname: Zhao
authors.forename: Xiaoming
authors.initials: X
authors.lastname: Li
authors.forename: Ivan S F
authors.initials: IS
authors.lastname: Chan
authors.forename: Paula W
authors.initials: PW
authors.lastname: Annunziato
authors.forename: Janie
authors.initials: J
authors.lastname: Parrino
mesh_terms: D000914:Antibodies, Viral / Q000097:blood*; D004311:Double-Blind Method; D005260:Female; D006562:Herpes Zoster / Q000276:immunology / Q000517:prevention & control*; D053061:Herpes Zoster Vaccine / Q000276:immunology*; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014611:Vaccination
chemical_list: D000914:Antibodies, Viral; D053061:Herpes Zoster Vaccine
keywords: herpes zoster; immunogenicity; zoster vaccine
references.citation: J Infect Dis. 2010 Apr 1;201(7):1024-30
references.pmid: 20170376
references.citation: MMWR Recomm Rep. 2008 Jun 6;57(RR-5):1-30; quiz CE2-4
references.pmid: 18528318
references.citation: N Engl J Med. 2002 Jul 4;347(1):26-34
references.pmid: 12097537
references.citation: J Med Virol. 2009 Jul;81(7):1310-22
references.pmid: 19475609
references.citation: Clin Infect Dis. 2010 Jul 15;51(2):197-213
references.pmid: 20550454
references.citation: Clin Vaccine Immunol. 2009 Sep;16(9):1381; author reply 1381-2
references.pmid: 19734522
references.citation: J Infect Dis. 2008 Nov 1;198(9):1327-33
references.pmid: 18774884
references.citation: J Infect Dis. 1995 Mar;171(3):701-4
references.pmid: 7876622
references.citation: J Infect Dis. 2008 Mar 15;197(6):825-35
references.pmid: 18419349
references.citation: J Clin Invest. 1980 Apr;65(4):869-78
references.pmid: 6244336
references.citation: J Clin Virol. 2012 Sep;55(1):46-50
references.pmid: 22771002
references.citation: Vaccine. 2006 Nov 17;24(47-48):6875-85
references.pmid: 17050042
references.citation: N Engl J Med. 2005 Jun 2;352(22):2271-84
references.pmid: 15930418
references.citation: J Med Virol. 2006 Dec;78(12):1679-87
references.pmid: 17063506
references.citation: Clin Infect Dis. 2012 Apr;54(7):922-8
references.pmid: 22291101
references.citation: J Clin Microbiol. 2006 Dec;44(12):4441-3
references.pmid: 17035500